Hepatology

    Title / AuthorCited byYear
    Chronic hepatitis B
    ASF Lok, BJ McMahon
    Hepatology 45 (2), 507-539
    16232007
    Diagnosis, management, and treatment of hepatitis C: An update
    MG Ghany, DB Strader, DL Thomas, LB Seeff
    Hepatology 49 (4), 1335-1374
    8302009
    Chronic hepatitis B: Update 2009
    ASF Lok, BJ McMahon
    Hepatology 50 (3), 661-662
    5662009
    Management of hepatitis B: Summary of a clinical research workshop
    JH Hoofnagle, E Doo, TJ Liang, R Fleischer, ASF Lok
    Hepatology 45 (4), 1056-1075
    4052007
    Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis
    G Garcia‐Tsao, AJ Sanyal, ND Grace, W Carey
    Hepatology 46 (3), 922-938
    3942007
    Molecular targeted therapies in hepatocellular carcinoma
    JM Llovet, J Bruix
    Hepatology 48 (4), 1312-1327
    3142008
    The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
    P Angulo, JM Hui, G Marchesini, E Bugianesi, J George, GC Farrell, ...
    Hepatology 45 (4), 846-854
    2972007
    Simplified criteria for the diagnosis of autoimmune hepatitis
    EM Hennes, M Zeniya, AJ Czaja, A Parés, GN Dalekos, EL Krawitt, ...
    Hepatology 48 (1), 169-176
    2792008
    Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management
    AS Lok, F Zoulim, S Locarnini, A Bartholomeusz, MG Ghany, ...
    Hepatology 46 (1), 254-265
    2592007
    Adding‐on versus switching‐to adefovir therapy in lamivudine‐resistant HBeAg‐negative chronic hepatitis B
    I Rapti, E Dimou, P Mitsoula, SJ Hadziyannis
    Hepatology 45 (2), 307-313
    2562007
    Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?
    T Livraghi, F Meloni, M Di Stasi, E Rolle, L Solbiati, C Tinelli, S Rossi
    Hepatology 47 (1), 82-89
    2542008
    MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations
    Y Ladeiro, G Couchy, C Balabaud, P Bioulac‐Sage, L Pelletier, ...
    Hepatology 47 (6), 1955-1963
    2312008
    The model for end‐stage liver disease (MELD)
    PS Kamath, W Kim
    Hepatology 45 (3), 797-805
    2282007
    Acute viral hepatitis increases liver stiffness values measured by transient elastography
    U Arena, F Vizzutti, G Corti, S Ambu, C Stasi, S Bresci, S Moscarella, ...
    Hepatology 47 (2), 380-384
    2232008
    Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
    S Boyault, DS Rickman, A de Reyniès, C Balabaud, S Rebouissou, ...
    Hepatology 45 (1), 42-52
    2212007
    Identification of metastasis‐related microRNAs in hepatocellular carcinoma
    A Budhu, HL Jia, M Forgues, CG Liu, D Goldstein, A Lam, KA Zanetti, ...
    Hepatology 47 (3), 897-907
    2182008
    Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients
    TL Kieffer, C Sarrazin, JS Miller, MW Welker, N Forestier, HW Reesink, ...
    Hepatology 46 (3), 631-639
    2132007
    Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis
    K Yamaguchi, L Yang, S McCall, J Huang, XX Yu, SK Pandey, S Bhanot, ...
    Hepatology 45 (6), 1366-1374
    2102007
    Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy
    DJ Tenney, RE Rose, CJ Baldick, KA Pokornowski, BJ Eggers, J Fang, ...
    Hepatology 49 (5), 1503-1514
    2062009
    Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: A retrospective study
    S Bruno, T Stroffolini, M Colombo, S Bollani, L Benvegnù, G Mazzella, ...
    Hepatology 45 (3), 579-587
    1992007
    1 - 20